Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent - PubMed (original) (raw)
Clinical Trial
. 2005 Dec;32(12):1384-91.
doi: 10.1007/s00259-005-1880-2. Epub 2005 Aug 26.
Affiliations
- PMID: 16133382
- DOI: 10.1007/s00259-005-1880-2
Clinical Trial
Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent
Rodney J Hicks et al. Eur J Nucl Med Mol Imaging. 2005 Dec.
Abstract
Purpose: The purpose of the study was to evaluate [(18)F]fluoromisonidazole (FMISO) PET in advanced head and neck cancer during hypoxia-targeting therapy.
Methods: Fifteen of 16 patients in a phase I trial of chemoradiation plus tirapazamine (specific cytotoxin for hypoxic cells) in advanced (T3/4 and/or N2/3) head and neck cancer underwent serial [(18)F]fluorodeoxyglucose (FDG) and FMISO PET. We have previously reported excellent early clinical outcome of these patients and now review FMISO PET results in the context of longer follow-up of this patient cohort.
Results: Based on blinded qualitative scoring by two readers, FMISO PET was positive in 13/15 patients at baseline: 12/15 of primary sites and 8/13 neck nodes were scored as positive. All sites of corresponding FDG and FMISO abnormality at baseline showed marked qualitative reduction of uptake within 4 weeks of commencing therapy, consistent with effective hypoxia-targeted therapy. With a median follow-up of 6.9 years, there have been only four locoregional failures, while three other patients have died of metachronous lung cancer. The 5-year overall survival was 50% (95% CI 27-73%), the 5-year failure-free survival was 44% (95% CI 22-68%) and the 5-year freedom from locoregional failure was 68% (95% CI 38-88%).
Conclusion: The high prevalence of hypoxia demonstrated on FMISO PET imaging is consistent with the advanced disease stage of these patients and would be expected to predict an adverse prognosis. Evidence of the early resolution of FMISO abnormality during treatment, associated with excellent locoregional control in this patient cohort, supports further investigation of hypoxia-targeting agents in advanced head and neck cancer.
Similar articles
- Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, Sexton M, D'Costa I, von Roemeling R. Rischin D, et al. J Clin Oncol. 2001 Jan 15;19(2):535-42. doi: 10.1200/JCO.2001.19.2.535. J Clin Oncol. 2001. PMID: 11208848 Clinical Trial. - Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S, Perrin R, Seidlitz A, Bandurska-Luque A, Zschaeck S, Zöphel K, Krause M, Steinbach J, Kotzerke J, Zips D, Troost EGC, Baumann M. Löck S, et al. Radiother Oncol. 2017 Sep;124(3):533-540. doi: 10.1016/j.radonc.2017.08.010. Epub 2017 Aug 23. Radiother Oncol. 2017. PMID: 28843726 - PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.
Kostakoglu L, Goldsmith SJ. Kostakoglu L, et al. J Nucl Med. 2004 Jan;45(1):56-68. J Nucl Med. 2004. PMID: 14734674 Review. - Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins.
Rischin D, Fisher R, Peters L, Corry J, Hicks R. Rischin D, et al. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S61-3. doi: 10.1016/j.ijrobp.2007.05.043. Int J Radiat Oncol Biol Phys. 2007. PMID: 17848298 Review. No abstract available.
Cited by
- Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.
Wilky BA, Loeb DM. Wilky BA, et al. Clin Exp Pharmacol. 2013 Jun;3(3):1000131. doi: 10.4172/2161-1459.1000131. Clin Exp Pharmacol. 2013. PMID: 25664221 Free PMC article. - Recent Development of Radiofluorination of Boron Agents for Boron Neutron Capture Therapy of Tumor: Creation of 18F-Labeled C-F and B-F Linkages.
Deng JP, Yu CS. Deng JP, et al. Pharmaceuticals (Basel). 2023 Jan 9;16(1):93. doi: 10.3390/ph16010093. Pharmaceuticals (Basel). 2023. PMID: 36678590 Free PMC article. Review. - Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.
Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Beck R, Reischl G, Picchio M, Machulla HJ, Wester HJ, Piert M. Souvatzoglou M, et al. Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1566-75. doi: 10.1007/s00259-007-0424-3. Epub 2007 Apr 20. Eur J Nucl Med Mol Imaging. 2007. PMID: 17447061 - Implantable sensor for local Cherenkov-excited luminescence imaging of tumor pO2 during radiotherapy.
Cao X, Gunn JR, Allu SR, Bruza P, Jiang S, Vinogradov SA, Pogue BW. Cao X, et al. J Biomed Opt. 2020 Nov;25(11):112704. doi: 10.1117/1.JBO.25.11.112704. J Biomed Opt. 2020. PMID: 33236619 Free PMC article. - Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, Chan K, Zanzonico PB, Greco C, Ling CC, Humm JL, Schöder H. Lee NY, et al. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):2-13. doi: 10.1016/j.ijrobp.2007.06.039. Epub 2007 Sep 14. Int J Radiat Oncol Biol Phys. 2008. PMID: 17869020 Free PMC article.
References
- Radiother Oncol. 1996 Oct;41(1):31-9 - PubMed
- J Clin Oncol. 2001 Jan 15;19(2):535-42 - PubMed
- Lancet. 2000 Mar 18;355(9208):949-55 - PubMed
- Int J Radiat Oncol Biol Phys. 1988 May;14(5):831-8 - PubMed
- Radiother Oncol. 2000 Oct;57(1):39-43 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical